Erlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell Lung Cancer
Status:
Terminated
Trial end date:
2017-08-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well erlotinib hydrochloride works before surgery in treating
patients with stage III non-small cell lung cancer. Erlotinib hydrochloride may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving
erlotinib hydrochloride before surgery may make the tumor smaller and reduce the amount of
normal tissue that needs to be removed.
Phase:
Phase 2
Details
Lead Sponsor:
Albert Einstein College of Medicine Albert Einstein College of Medicine of Yeshiva University